|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.40/-1.34
|
企业价值
1.87B
|
资产负债 |
每股账面净值
2.84
|
现金流量 |
现金流量率
--
|
损益表 |
收益
2.07M
|
每股收益
0.03
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/15 14:19 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company's focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |